Drug · Small Molecule

Cyproterone Acetate

CI-DRUG-00000167Explore in graph →NCIt C1059 CHEMBL139835 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	1	6	9	0	—	—	1987-05
Malignant Prostate Neoplasm	Phase3	Phase 3	0	0	5	6	0	—	—	1987-05

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AR Mutation1
Bicalutamide + Cyproterone Acetate

Clinical trials

Trials with this intervention (12)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–12 of 12 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05316935	GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients	recruiting	Phase 2 / Phase 3	80	Xiaojun ChenOTHER	1	Sep 10, 2026	clinicaltrials
NCT02460445	Phlebotomy and Polycystic Ovary Syndrome	completed	N/A	37	Manuel Luque Ramírez

Molecule

Record

Kind: Small Molecule
Mechanism: Androgen Receptor antagonist; Glucocorticoid receptor antagonist; Progesterone receptor agonist
Targets: 3 genes
Aliases: 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-, 6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate, Androcur, Androcur 10, Andro-Diane, Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate, Ciproterona, CyPat, Cyprone, Cyprostat, Cyproteronazetat, Cyproterone, Cyproterone 17.alpha.-acetate, Cyproterone Acetate, Cyproteroni Acetas, Diane, Dianette, NSC-81430, SH 714, SH714

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.